Provided by Tiger Trade Technology Pte. Ltd.

Fulcrum Therapeutics

3.84
+0.01000.26%
Post-market: 3.840.00000.00%16:10 EDT
Volume:855.86K
Turnover:3.27M
Market Cap:292.98M
PE:-3.17
High:3.86
Open:3.84
Low:3.78
Close:3.83
52wk High:15.74
52wk Low:2.83
Shares:76.30M
Float Shares:63.49M
Volume Ratio:0.27
T/O Rate:1.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2104
EPS(LYR):-1.1819
ROE:-32.38%
ROA:-19.59%
PB:0.94
PE(LYR):-3.25

Loading ...

This Biotech Stock Plunges 48%. Its Sickle Cell Drug Has 'No Viable Path Forward.' -- Barrons.com

Dow Jones
·
Jun 02

Top Premarket Decliners

MT Newswires Live
·
Jun 02

BUZZ-U.S. STOCKS ON THE MOVE-Microchip Technology, Marvell Technology, Generac

Reuters
·
Jun 02

Fulcrum Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
Jun 02

HC Wainwright Downgrades Fulcrum Therapeutics to Neutral From Buy, Adjusts PT to $3 From $25

MT Newswires Live
·
Jun 02

Fulcrum plummets 50% after scrapping lead sickle-cell drug on FDA concerns

Reuters
·
Jun 02

Fulcrum Therapeutics Inc : H.c. Wainwright Cuts Target Price to $3 From $25

THOMSON REUTERS
·
Jun 02

Fulcrum Therapeutics downgraded to Market Perform from Outperform at Leerink

TIPRANKS
·
Jun 02

Fulcrum Therapeutics Shares Slide 49.4% to $3.25 Premarket After Co Scraps Sickle Cell Drug Development

THOMSON REUTERS
·
Jun 02

Piper double downgrades Fulcrum after sickle cell development stopped

TIPRANKS
·
Jun 02

U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik

Reuters
·
Jun 02

Fulcrum Therapeutics Inc : Truist Securities Cuts to Hold From Buy; Cuts Target Price to $4 From $17

THOMSON REUTERS
·
Jun 02

Fulcrum Therapeutics downgraded to Underweight from Overweight at Piper Sandler

TIPRANKS
·
Jun 02

Fulcrum Therapeutics downgraded to Hold from Buy at Stifel

TIPRANKS
·
Jun 02

BUZZ-Fulcrum Therapeutics falls after scrapping sickle cell drug development

Reuters
·
Jun 02

Fulcrum discontinues pociredir program in SCD, initiates strategic review

TIPRANKS
·
Jun 02

Fulcrum Therapeutics Ends Sickle Cell Disease Drug Development, Starts Strategic Review

Dow Jones
·
Jun 02

Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review

THOMSON REUTERS
·
Jun 02

Fulcrum Therapeutics - to Explore Merger, Acquisition, or Other Strategic Transactions

THOMSON REUTERS
·
Jun 02

Fulcrum Therapeutics - Initiates Efforts to Reduce Operating Expenses and Preserve Capital

THOMSON REUTERS
·
Jun 02